Loading...

China Resources Pharmaceutical Group Limited

3320.HK•HKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$5.31
HK$-0.04(-0.75%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the last four quarters, China Resources Pharmaceutical Group Limited's revenue moved from $128.39B in Q4 2022 to $139.35B in Q2 2024. Operating income in Q2 2024 was $7.57B, with a strong operating margin of 5%. Despite fluctuations in R&D and SG&A expenses, EBITDA for China Resources Pharmaceutical Group Limited remained robust at $10.46B, reflecting operational efficiency. Net income rose to $2.82B, with an EPS of $0.45. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;